Teva Pharmaceutical Industries Ltd. ADR logo

Teva Pharmaceutical Industries Ltd. ADR (0LER)

Market Closed
17 Jul, 15:30
LSE LSE
$
32. 00
+0.3
+0.9464%
$
- Market Cap
- P/E Ratio
0.34% Div Yield
3,827 Volume
- Eps
$ 31.7
Previous Close
Add Transaction
Day Range
31.48 32.72
Year Range
14.99 37.3
Want to track 0LER and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0LER closed yesterday higher at $32, an increase of 0.9464% from Thursday's close, completing a monthly decrease of -2.439% or -$0.8. Over the past 12 months, 0LER stock gained 2.2364%.
0LER pays dividends to its shareholders, with the most recent payment made on Dec 12, 2017. The next estimated payment will be in 12 Mar 2018 on Mar 12, 2018 for a total of $0.085.
The last earnings report, released on May 06, 2026, missed the consensus estimates by -0.55%. On average, the company has fell short of earnings expectations by -0.3891%, based on the last three reports.
Teva Pharmaceutical Industries Ltd. ADR has completed 4 stock splits, with the recent split occurring on Jul 01, 2004.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NYSE (USD).

0LER Chart

Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.

Marketbeat | 5 days ago
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

Seekingalpha | 1 week ago
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Fool | 1 week ago

Teva Pharmaceutical Industries Ltd. ADR (0LER) FAQ

What is the stock price today?

The current price is $32.00.

On which exchange is it traded?

Teva Pharmaceutical Industries Ltd. ADR is listed on LSE.

What is its stock symbol?

The ticker symbol is 0LER.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.34%.

What is its market cap?

As of today, no market cap data is available.

Has Teva Pharmaceutical Industries Ltd. ADR ever had a stock split?

Teva Pharmaceutical Industries Ltd. ADR had 4 splits and the recent split was on Jul 01, 2004.

Teva Pharmaceutical Industries Ltd. ADR Profile

Specialty Retail Industry
Consumer Discretionary Sector
Richard D. Francis CEO
LSE Exchange
881624209 CUSIP
IL Country
37,000 Employees
12 Dec 2017 Last Dividend
1 Jul 2004 Last Split
- IPO Date

Overview

Teva Pharmaceutical Industries Limited is a prominent global company with a focus on developing, manufacturing, marketing, and distributing a wide range of pharmaceutical products. Its operations span across North America, Europe, Israel, and other international markets. Teva's portfolio includes generic medicines, specialty medicines, and biopharmaceutical products, catering to various dosage forms and therapeutic areas. With a history dating back to 1901, the company has established itself as a leader in the pharmaceutical industry, headquartered in Tel Aviv, Israel. Teva is known for its contribution to central nervous system (CNS), respiratory, and oncology therapeutic areas, providing active pharmaceutical ingredients and contract manufacturing services, alongside operating an out-licensing platform for other pharmaceutical companies. Teva's commitment to healthcare and therapeutic advancements is evident through its collaboration agreements with MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., as well as a license agreement with MODAG GmbH.

Products and Services

BENDEKA and TREANDA injections: Used for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, these injections underscore Teva's focus on oncology.

GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM: These products exemplify Teva's commitment to providing supportive care in oncology, including treatments for neutropenia and arsenic trioxide for leukemia.

COPAXONE: This flagship product for the treatment of relapsing forms of multiple sclerosis highlights Teva's innovation in CNS therapies.

AJOVY: A treatment for the preventive care of migraine in adults, AJOVY is part of Teva's specialty medicine range aimed at improving quality of life for migraine sufferers.

AUSTEDO: Focused on neurodegenerative and movement disorders, AUSTEDO is used for treating conditions associated with Huntington's disease and tardive dyskinesia.

UZEDY: This antipsychotic is used for the treatment of schizophrenia, reflecting Teva's ongoing development in CNS health.

Respiratory Products: Teva offers a suite of respiratory products like ProAir RespiClick inhalation powder, QVAR for asthma, BRALTUS, CINQAIR/CINQAERO injection, DuoResp Spiromax, and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder, addressing a broad spectrum of respiratory conditions.

OTC Products: Teva's over-the-counter (OTC) offerings under brands such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA, cater to a variety of everyday health needs, from skincare to cold and flu relief.

In addition to its broad spectrum of pharmaceutical products, Teva Pharmaceutical Industries Limited also provides active pharmaceutical ingredients and contract manufacturing services, demonstrating its versatility and comprehensive approach to healthcare solutions.

Contact Information

Address: 124 Dvora Hanevi'a Street
Phone: 972 3 914 8213